## Review setup
- **Input scope** Abstract only
- **Assessment boundary** The abstract as provided, without access to the full manuscript, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors report a proof-of-principle study using plasma cell-free DNA (cfDNA) sequencing to generate nucleosome profiles, which reflect tissue-of-origin and transcription factor activities. They applied machine learning classifiers to discriminate benign from malignant breast lesions, reporting area under the curve (AUC) values of 0.777 for transcription factor activity and 0.824 for transcription factor-binding site accessibility profiles.
- **Visible evidence base** Abstract text only; no figures, tables, methods details, or statistical analyses are available
- **Missing materials affecting confidence** Full methods, cohort characteristics, sequencing platform and depth, feature selection procedures, classifier architecture and validation strategy, calibration metrics, confidence intervals, and any external validation data

## Reviewer
- **Overall assessment** The abstract presents a clinically relevant question and a plausible noninvasive approach. However, the evidence provided is insufficient to evaluate the technical soundness, robustness, or generalizability of the reported classifiers. The claims are promising but not established from the supplied material.
- **Who would be interested in the results, and why** Researchers and clinicians in oncology, particularly breast cancer diagnostics, liquid biopsy, and precision medicine. The potential to reduce unnecessary invasive biopsies for benign breast lesions would interest translational researchers and clinical diagnosticians.
- **Major strengths** The study addresses a clear clinical need with a noninvasive approach. The use of cfDNA nucleosome profiles to infer transcription factor activity is mechanistically grounded. The inclusion of benign and malignant lesion cohorts, as well as healthy controls, is appropriate for the stated aim.
- **Major Concerns**  
  - **Concern ID** R1-M1  
  - **Severity** Major  
  - **Blocking** Yes  
  - **Axis** Technical soundness  
  - **Claim pointer** The classifiers can accurately distinguish benign from malignant breast lesions with AUC values of 0.777 and 0.824.  
  - **Evidence pointer** Abstract, Results section; location not provided  
  - **Concern** The abstract reports AUC values but provides no information on classifier training, validation, or test set separation. Without explicit cross-validation or independent test set results, the reported performance may reflect overfitting.  
  - **Why it matters** AUC values derived from training data or without proper validation are not reliable indicators of real-world diagnostic performance. Overstated accuracy could mislead clinical translation.  
  - **Resolution test** Provide a clear description of the data splitting strategy, cross-validation scheme, and performance metrics on held-out or external validation cohorts.  
  - **Concern ID** R1-M2  
  - **Severity** Major  
  - **Blocking** Yes  
  - **Axis** Reproducibility  
  - **Claim pointer** cfDNA-based nucleosome profiles reflect various tissues of origin and transcription factor activities in benign and malignant breast lesions.  
  - **Evidence pointer** Abstract, Results section; location not provided  
  - **Concern** The abstract does not specify how tissue-of-origin or transcription factor activity was inferred, nor which reference data or computational methods were used. The biological interpretation is central to the claim but is not verifiable from the abstract.  
  - **Why it matters** Without methodological detail, the mechanistic claim cannot be assessed for validity or reproducibility.  
  - **Resolution test** Describe the computational pipeline, reference datasets, and statistical thresholds used to infer transcription factor activity and tissue-of-origin.  
  - **Concern ID** R1-M3  
  - **Severity** Major  
  - **Blocking** Yes  
  - **Axis** Generalizability  
  - **Claim pointer** The methodology can noninvasively discriminate benign from malignant breast lesions.  
  - **Evidence pointer** Abstract, Conclusions section; location not provided  
  - **Concern** The abstract does not report whether the classifiers were tested on independent cohorts or whether performance varied by clinical or pathological subgroups. The cohort composition and inclusion criteria are not described.  
  - **Why it matters** Without external validation or subgroup analysis, the generalizability of the classifiers to broader patient populations remains unknown.  
  - **Resolution test** Provide external validation results or clearly state the limitations regarding cohort diversity and generalizability.

- **Minor Comments**  
  - **Concern ID** R1-m1  
  - **Severity** Minor  
  - **Axis** Clarity  
  - **Affected element** Abstract, Methods  
  - **Evidence pointer** Abstract, Methods section; location not provided  
  - **Issue** The abstract states that machine learning classifiers were built but does not specify which algorithms were used.  
  - **Required correction** Name the classifier types and any hyperparameter tuning procedures.  
  - **Concern ID** R1-m2  
  - **Severity** Minor  
  - **Axis** Statistical reporting  
  - **Affected element** Abstract, Results  
  - **Evidence pointer** Abstract, Results section; location not provided  
  - **Issue** AUC values are reported without confidence intervals or p-values.  
  - **Required correction** Include confidence intervals and, where applicable, statistical comparisons between classifiers.  
  - **Concern ID** R1-m3  
  - **Severity** Minor  
  - **Axis** Clinical context  
  - **Affected element** Abstract, Background  
  - **Evidence pointer** Abstract, Background section; location not provided  
  - **Issue** The abstract does not state the clinical setting or intended use of the classifier, such as triage before biopsy or adjunct to imaging.  
  - **Required correction** Clarify the intended clinical application and the target patient population.

## Risk / unsupported claims
- The claim that cfDNA-based nucleosome profiles reflect tissue-of-origin and transcription factor activities is not supported by the abstract alone, as no methodological or validation details are provided.
- The reported AUC values are presented without confidence intervals, validation strategy, or external testing, making the performance claims unverifiable from the supplied material.
- The conclusion that the methodology is established for noninvasive discrimination is premature given the lack of technical and statistical detail in the abstract.

## Assessment against Nature-style criteria
- **Originality** The approach is not entirely novel, as cfDNA nucleosome profiling has been explored in other cancers, but its application to benign versus malignant breast lesion discrimination is a reasonable extension. The abstract does not demonstrate a conceptual leap.
- **Scientific importance** The clinical question is important, and a reliable noninvasive test could reduce unnecessary biopsies. However, the abstract does not provide sufficient evidence to assess the potential impact.
- **Interdisciplinary readership** The topic bridges oncology, molecular diagnostics, and computational biology, which could attract a broad readership if the methods and results are robustly presented.
- **Technical soundness** Not assessable from the abstract. Key technical details on sequencing, feature extraction, and classifier validation are absent.
- **Readability for nonspecialists** The abstract is generally clear but uses technical terms without explanation, which may limit accessibility for a general scientific audience.

## Recommendation posture
Currently not established from the provided evidence. The abstract presents a plausible and clinically relevant approach, but the lack of methodological detail, validation strategy, and statistical rigor prevents a supportive recommendation. The case would be strengthened by full methods, validation results, and transparent reporting of classifier performance.